SHANGHAI – In a press conference, the Ministry of Public Security (MPS) announced that its 10-month bribery investigation into the China operations of Glaxosmithkline plc had come to a close. The case will be transferred to provincial prosecutors in Changsha to further review the case. Read More
Just five years after its founding and after raising approximately $100 million across four venture rounds, ZS Pharma Inc. followed the well-trod path toward an initial public offering (IPO), where it will seek to raise up to $86 million. Read More
LONDON – The EMA issued an update on joint U.S.-European efforts to tackle the rising tide of antimicrobial resistance, detailing progress in converging the EMA and FDA regulatory requirements in the development of new antibacterial drugs. Read More
HONG KONG – Powered by sales of biologics and other pharmaceutical products, Wuxi Pharmatech Inc. posted strong first quarter results hurt only by a depreciation in the Chinese RMB. Read More
LONDON – A massive study exploring the ways in which common genetic variants influence the levels of various metabolites in human blood has delivered a treasure trove of information ready for scientists, researchers and drug developers to explore. Read More
Amid the tumbling capital markets for most equities Thursday, San Diego-based Sorrento Therapeutics Inc. said it expects to generate $25 million in gross proceeds from an underwritten public offering of about 4.8 million shares of common stock at $5.25 each. Read More
Novelmed Therapeutics Inc., of Cleveland, reported data using its humanized monoclonal antibody in two well-established models of osteoarthritis, characterized by osteophyte formation and cartilage loss. Read More
Diffusion Pharmaceuticals LLC, of Charlottesville, Va., said it reached the one-year interim endpoint for its phase I/II trial of trans sodium crocetinate (TSC), its lead compound for cancer. Read More
Actavis plc., of Dublin, said it reached an agreement with Janssen Pharmaceuticals Inc. (JPI), a unit of New Brunswick, N.J.-based Johnson & Johnson, to continue supplying the authorized generic version of JPI's Concerta (methylphenidate hydrochloride extended-release tablets). Read More
Eisai Ltd., of Hatfield, UK, said data from a three-year safety study of Fycompa (perampanel), published online in Epilepsia, demonstrate that the epilepsy treatment controls and reduces seizures over sustained periods. Read More
